MRNA Mar 2025 130.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
At close: 03:30PM EDT
| Previous Close | 41.90 |
| Open | 35.35 |
| Bid | 32.05 |
| Ask | 37.25 |
| Strike | 130.00 |
| Expire Date | 2025-03-21 |
| Day's Range | 35.35 - 35.35 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 45 |
Investor's Business DailyModerna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK
The FDA approved Moderna's RSV vaccine, allowing the biotech to launch its second-ever product. But Moderna stock retreated.
ACCESSWIREModerna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes CAMBRIDGE, MA / ACCESSWIRE / May 31, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) ...
Investor's Business DailyIs Moderna Stock A Buy As The U.S. Government Mulls Its Bird Flu Vaccine?
Moderna stock is on the rise again as investors focus on the potential need for a bird flu vaccine. Is MRNA stock a buy right now?
© 2024 Yahoo. All rights reserved.